Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Heart Rate Variability as a Marker for Titrating High Flow Nasal Cannula Therapy in Patients with Respiratory Failure

EF 2025-26

Résumé
High-flow nasal cannula (HFNC) is often used in patients with respiratory failure to enhance oxygen delivery and reduce work of breathing. However, the optimal strategy to titrate HFNC support remains uncertain. Reducing flow rates prematurely can increase work of breathing and prolong ICU stay, while unnecessary prolongation can increase costs. Currently, evidence to guide titration is limited. This study aims to investigate whether heart rate variability (HRV) can serve as a marker of the adequacy of HFNC support during flow titration. HRV, the variation in the intervals between heartbeats, reflects the level of autonomic nervous system activity in response to cardiopulmonary stress. Higher HRV indicates freedom within a system to adapt, whereas low HRV signifies a more constrained, stressed system. In critically ill patients, reduced HRV is associated with poor outcomes, including ventilator weaning failure and mortality. Because the cardiorespiratory systems are closely linked via the parasympathetic branch of the autonomic nervous system, changes in respiratory function may affect HRV before more conventional signs of respiratory distress become apparent. We will enroll 20 adult patients on HFNC. Each patient will undergo stepwise titration of flow, beginning at a flow rate of 50 L/min and progressively reducing flow in steps of 10 L/min to 20 L/min or the lowest tolerable flow rate. Heart rate and respiratory parameters will be monitored using electrocardiography (ECG) and electrical impedance tomography for 20 minutes at each setting. HRV will be analyzed from the ECG waveform, using an open-source python package. If HRV proves to be a sensitive marker of respiratory stress, it could be measured in real-time on HFNC devices to guide HFNC therapy optimization.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572892
Name
Alves Renda K Amaral Marcela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Heart Rate Variability as a Marker for Titrating High Flow Nasal Cannula Therapy in Patients with Respiratory Failure
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cardiorespiratory System; Heart Rate Variability; High-Flow Nasal Cannula; Respiratory Distress
Abstract
High-flow nasal cannula (HFNC) is often used in patients with respiratory failure to enhance oxygen delivery and reduce work of breathing. However, the optimal strategy to titrate HFNC support remains uncertain. Reducing flow rates prematurely can increase work of breathing and prolong ICU stay, while unnecessary prolongation can increase costs. Currently, evidence to guide titration is limited. This study aims to investigate whether heart rate variability (HRV) can serve as a marker of the adequacy of HFNC support during flow titration. HRV, the variation in the intervals between heartbeats, reflects the level of autonomic nervous system activity in response to cardiopulmonary stress. Higher HRV indicates freedom within a system to adapt, whereas low HRV signifies a more constrained, stressed system. In critically ill patients, reduced HRV is associated with poor outcomes, including ventilator weaning failure and mortality. Because the cardiorespiratory systems are closely linked via the parasympathetic branch of the autonomic nervous system, changes in respiratory function may affect HRV before more conventional signs of respiratory distress become apparent. We will enroll 20 adult patients on HFNC. Each patient will undergo stepwise titration of flow, beginning at a flow rate of 50 L/min and progressively reducing flow in steps of 10 L/min to 20 L/min or the lowest tolerable flow rate. Heart rate and respiratory parameters will be monitored using electrocardiography (ECG) and electrical impedance tomography for 20 minutes at each setting. HRV will be analyzed from the ECG waveform, using an open-source python package. If HRV proves to be a sensitive marker of respiratory stress, it could be measured in real-time on HFNC devices to guide HFNC therapy optimization.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Alves Renda K Amaral, Marcela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~